A new update has been made to the growth hormone therapy program. Omnitrope, the preferred somatropin brand, is now the medication of preferred over others. This drug was selected based on safety, efficacy, delivery device, and cost.
- On November 18, 2011, Omnitrope moved from Tier 4 to Tier 3.
- On January 1, 2012, all other growth hormones were moved to Tier 4.
- By March 1, 2012, any BCBSNC member who is not on Omnitrope will be required to have their physician submit documentation demonstrating a medical explanation on why they should be prescribed a different drug.